Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Consensus Recommendation of “Hold” from Analysts

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been assigned an average recommendation of “Hold” from the twelve ratings firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $78.5556.

Several research firms have weighed in on HALO. Benchmark boosted their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. Wall Street Zen lowered Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Weiss Ratings lowered Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Tuesday, February 24th. Finally, HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, January 29th.

Halozyme Therapeutics Stock Up 0.8%

NASDAQ:HALO opened at $63.60 on Wednesday. The firm has a market capitalization of $7.53 billion, a price-to-earnings ratio of 25.54, a price-to-earnings-growth ratio of 0.26 and a beta of 1.03. Halozyme Therapeutics has a twelve month low of $47.50 and a twelve month high of $82.22. The stock’s 50 day moving average price is $69.67 and its two-hundred day moving average price is $69.09. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of $1.92 by ($2.16). The company had revenue of $451.77 million for the quarter, compared to analyst estimates of $446.13 million. Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The firm’s revenue for the quarter was up 51.6% compared to the same quarter last year. During the same period last year, the firm earned $1.26 EPS. Equities research analysts expect that Halozyme Therapeutics will post 4.73 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $64.24, for a total transaction of $1,284,800.00. Following the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $49,322,187.20. The trade was a 2.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Cortney Caudill sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $67.80, for a total value of $1,356,000.00. Following the transaction, the chief operating officer directly owned 14,366 shares in the company, valued at $974,014.80. The trade was a 58.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 118,857 shares of company stock worth $8,279,587 over the last three months. 2.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. DLD Asset Management LP increased its holdings in shares of Halozyme Therapeutics by 20.0% during the 3rd quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock worth $2,200,200,000 after acquiring an additional 5,000,000 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Halozyme Therapeutics by 29.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 3,290,665 shares of the biopharmaceutical company’s stock worth $241,337,000 after acquiring an additional 749,484 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Halozyme Therapeutics by 1.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,104,157 shares of the biopharmaceutical company’s stock worth $141,613,000 after acquiring an additional 25,731 shares during the last quarter. Norges Bank acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $128,201,000. Finally, William Blair Investment Management LLC acquired a new position in shares of Halozyme Therapeutics during the 4th quarter worth approximately $124,031,000. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.